Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Ascendis Health's journey from near-bankruptcy to profitability showcases how strategic leadership and financial discipline ...

European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, rising 1.12% to 1,433.84 on the S&P Europe Select ADR Index. From continental Europe, ...

Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...

Despite the day’s gains, Ascendis shares remain down over 10% in the past year and trade about 54% below the average analyst target of $193.49, according to Koyfin data. The company’s stock ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a ...

Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $55,812.96 today based on a price of $151.93 for ASND at the time of writing.

Check Out Our Latest Analysis on Ascendis Pharma A/S Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19 ...

Ascendis Pharma A/S (NASDAQ:ASND) defied analyst predictions to release its annual results, which were ahead of market expectations. The overall earnings picture was okay, with revenues of €364m ...

COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2024 ...

Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company with a $9.07 billion market capitalization focused on developing transformative therapies for rare endocrine disorders, has been ...